#news #biotech Galmed’s stock soars after phase 2 NASH results

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Galmed’s stock soars after phase 2 NASH results .Galmed Pharmaceuticals unveiled top-line results from a year-long phase 2b study of its oral treatment for nonalcoholic steatohepatitis, demonstrating a statistically significant reduction in liver fat without worsening fibrosis.

from FierceBiotech: Biotech https://ift.tt/2t2rA4f